Using evidence of multiple study designs in systematic reviews by Peinemann, F.
  
 
Using evidence of multiple study designs in
systematic reviews
Citation for published version (APA):
Peinemann, F. (2015). Using evidence of multiple study designs in systematic reviews. Maastricht:
Datawyse / Universitaire Pers Maastricht.
Document status and date:
Published: 01/01/2015
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
213 
 
Valorisation 
The work of the thesis gained extensive insight into the using of evidence of multiple 
study designs in systematic reviews. A review of a comprehensive literature showed a 
tendency that nonrandomized studies should be conducted and integrated in system-
atic reviews to complement available randomized controlled trials or replace lacking 
those trials. The risk of presenting uncertain results without knowing for sure the di-
rection and magnitude of the effect holds true for both nonrandomized and random-
ized controlled trials. The consideration of registry analyses and case reports can be 
very helpful to draw attention to possible dangerous and life-threatening events be-
yond the scope of a randomized controlled trial. Ethical concerns may prevent trials 
with a random allocation of patients to treatment groups. Health-related quality of life 
may vary considerably if the treatment options are characterized by varying degrees of 
invasiveness. In this case, reluctance of patients and physicians alike to participate in 
randomization corroborates the consideration of alternative approaches. The work 
showed the importance of using multiple study designs in systematic reviews and pro-
vided many examples. A decision tree was constructed to facilitate the choosing of 
study designs for particular research questions, as shown below. Length of follow-up, 
frequency of events, and type of outcomes were the main decision points. It was en-
sured that the preset pathways retain sufficient flexibility to consider ethical and prac-
tical issues as well as unavailable best evidence. The appropriateness of the pathways 
of the decision tree was confirmed by backtracing four systematic reviews. The theory-
based algorithm proved to be useful in various practical situations and helped to 
choose the appropriate study designs for inclusion in each tested systematic review. 
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Relevance 
The use of multiple study designs in systematic reviews clearly showed that various 
study designs increased the information that should be considered in decision-making. 
The impact of the extra information may not be foreseen very well. The extra infor-
mation may complement the best available evidence based on randomized controlled 
trials by adding new important data and by opening the horizon to bring attention to 
issues that may be overlooked but are nevertheless pertinent to health care. Some-
times information from multiple study designs can induce prudence in those who de-
cide about an acclaimed new intervention. For example, randomized controlled trials 
may not be the typical study design to provide sufficient evidence for market with-
drawals. 
Target groups 
The algorithm is foreseen to function as a tool helping to bring seminal features of a 
systematic review to the attention of anyone who is planning to conduct a systematic 
review. This includes persons working in organizations or institutes that prepare health 
technology assessment reports, evidence reports, or systematic reviews on health care 
interventions. It helps to reorientate oneself to major features of the studies eligible 
for an evaluation of a health care intervention. This is not meant to add a new regula-
tion, but the benefit is the provision of awareness of the value of different study de-
signs in systematic reviews. The intention is to provide a guide that might be used fully 
or partially by persons who are going to prepare a systematic review. While conducting 
a systematic review, it may be important at an early time point to identify the relevant 
and the most appropriate study designs necessary to find answers for a variety of pre-
specified outcomes. It might also be of interest for persons who evaluate the quality of 
systematic reviews and might want to check whether all study relevant designs have 
indeed been considered. This may include individual physicians who intend to make 
evidence-based decisions on the treatment of their patients, although it will not be 
easy for busy clinicans to do so. It should also include persons with positions on a more 
collective level of evidence synthesis, such as scientists of academic institutions and 
members of guideline committees who critically assess the published evidence on 
various health care interventions, and staff of governmental administrations that make 
political decisions on the reimbursement of public health care services. 
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